In Vitro antibacterial activity of AZD0914 against human mycoplasmas and ureaplasmas

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3627-3629

  Waites, Ken B ^a   Crabb, Donna M ^a   Duffy, Lynn B ^a   Huband, Michael D ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZD 0914; AZITHROMYCIN; DOXYCYCLINE; GYRASE INHIBITOR; LEVOFLOXACIN; PYRIMIDINE DERIVATIVE; RNA 23S; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BARBITURIC ACID DERIVATIVE; SPIRO COMPOUND; ZOLIFLODACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA GENITALIUM; MYCOPLASMA HOMINIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PRIORITY JOURNAL; UREAPLASMA PARVUM; UREAPLASMA UREALYTICUM; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; MYCOPLASMA; UREAPLASMA;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BARBITURATES; DOXYCYCLINE; HUMANS; LEVOFLOXACIN; MICROBIAL SENSITIVITY TESTS; MYCOPLASMA; MYCOPLASMA GENITALIUM; MYCOPLASMA PNEUMONIAE; SPIRO COMPOUNDS; UREAPLASMA;

EID: 84929613792     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04945-14     Document Type: Article

References (10)

1. Kohlhoff SA, Huband MD, Hammerschlag MR. 2014. In vitro activity of AZD0914, a novel DNA gyrase inhibitor against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 58:7595-7596. http://dx.doi.org/10.1128/AAC.03920-14.
2. Jacobsson S, Golparian D, Alm RA, Huband MD, Mueller J, Jensen JS, Ohnishi M, Unemo M. 2014. High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea. Antimicrob Agents Chemother 58:5585-5588. http://dx.doi.org/10.1128/AAC.03090-14.
3. Huband MD, Bradford PA, Otterson LG, Basarab GS, Kutschke AC, Giacobbe RA, Patey SA, Alm RA, Johnstone MR, Potter MA, Miller PF, Mueller JP. 2015. In vitro antibacterial activity of AZD0914: a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria. Antimicrob Agents Chemother 59:467-474. http://dx.doi.org/10.1128/AAC.04124-14.
4. Li X, Atkinson TP, Hagood JA, Makris C, Duffy LB, Waites KB. 2009. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates with real-time PCR. Pediatr Infect Dis J 28:693-698. http://dx.doi.org/10.1097/INF.0b013e31819e3f7a.
5. Duffy LB, Glass JI, Hall G, Avery R, Rackley R, Peterson S, Waites KB. 2006. Fluoroquinolone resistance in Ureaplasma parvum in the United States. J Clin Microbiol 44:1590-1591. http://dx.doi.org/10.1128/JCM.44.4.1590-1591.2006.
6. Xiao X, Crabb DM, Duffy LB, Paralanov V, Glass JI, Hamilos DL, Waites KB. 2011. Mutations in ribosomal proteins and ribosomal RNA confer macrolide resistance in Ureaplasma spp. Int J Antimicrob Agents 37:377-379. http://dx.doi.org/10.1016/j.ijantimicag.2010.12.012.
7. Clinical and Laboratory Standards Institute. 2011. Methods for antimicrobial susceptibility testing of human mycoplasmas; approved guideline. CLSI document M43-A. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Waites KB, Crabb DM, Bing X, Duffy LB. 2003. In vitro susceptibilities and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 47:161-165. http://dx.doi.org/10.1128/AAC.47.1.161-165.2003.
9. th ed. ASM Press, Washington, DC.
10. Waites KB, Lysynyansky I, Bebear CM. 2014. Emerging antimicrobial resistance in mycoplasmas of humans and animals, p 289-322. In Browning G, Citti C (ed), Mollicutes: molecular biology and pathogenesis. Caister Academic Press, Norfolk, United Kingdom.